Tolerabilidad de la desvenlafaxina en una muestra psiquiátrica ambulatoria española

  1. Erkoreka, Leire
  2. Arroita, Ariane
  3. Pérez-Cabeza, Lucía
  4. Navarro, Bárbara
Journal:
Norte de Salud Mental

ISSN: 1578-4940

Year of publication: 2015

Issue Title: Junio 2015

Volume: 13

Issue: 52

Pages: 81-86

Type: Article

DIALNET GOOGLE SCHOLAR lock_openDialnet editor

More publications in: Norte de Salud Mental

Abstract

Introduction. Desvenlafaxine is a serotonin and norepinephrine reuptake inhibitor recently approved in Spain, with a potentially promising tolerability and interaction profile. Most available data on side-effects are based on phase III clinical trials (RCT-III) carried out by laboratories, and there are still no tolerability studies on Spanish population. Therefore, the aim of this study is to evaluate the side effects incidence and discontinuation rate in a Spanish psychiatric setting and compare them with data from RCT-III. Methods: Demographic variables are collected and the “UKU side effects rating scale” is administered after drug titration period in a psychiatric outpatient sample with depressive symptomatology (n=39). The incidence of side effects and discontinuation rate are then compared with the results obtained from RCT-III. Results: The most frequently reported side effects in our sample are “sleepiness/sedation” (10,25%) and “increased tendency to sweating” (10,25%). In comparison with results from RCT-III, there is a significantly greater incidence of “concentration difficulties” (7,69% vs 1,24%, p=0,0091) and “paraesthesias” (7,69% vs 1,62%, p=0,03) and a lower incidence of “nausea/vomiting” (5,12% vs 32%, p=0,0007) and “headache” (7,69% vs 23,37%, p=0,036) in the Spanish sample. There are no statistically significant differences among the rest of SE or discontinuation rate. Conclusions: Despite these differences, results obtained from RCT-III seem to be comparable to Spanish population. Regarding potential advantages of desvenlafaxine with respect to other pharmacologic alternatives, and based on available literature, the former has apparently a better sexual side-effect profile and weight gain is less common than with other antidepressants.

Bibliographic References

  • Sansone RA, Sansone LA. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci. 2014; 11(3-4): 37-42.
  • Cardoner Álvarez N. Desvenlafaxina, un nuevo IRSN para el tratamiento de la depresión mayor: revisión de la literatura. Psiq Biol. 2013; 20(1-2): 2-7.
  • Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, et al. Efficacy, safety and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/d for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008; 23: 243-253.
  • Clayton A, Kornstein SG, Rosas G, Guico-Pavia C, Tourian KA. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr. 2009; 14(4): 183-195.
  • Liebowitz MR, Tourian KA. Efficacy, safety and tolerability of desvenlafaxine 50 mg/d for the treatment of major depressive disorder: a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. [revista electrónica] 2010; 12(3). [accedido 18 Jul 2014]. Disponible en: http://www.psychiatrist.com/PCC/article/ Pages/2010/v12n03/09r00845blu.aspx
  • Tourian KA, Pitrosky B, Padmanabhan SK, Rosas GR. A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder. Prim Care Companion CNS Disord. [revista electrónica] 2011; 13(2). [accedido 18 Jul 2014]. Disponible en: http://www. psychiatrist.com/PCC/article/Pages/2011/ v13n02/10m00977blu.aspx
  • Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ. Symptomatic and functional improvement in employed depressed patients. A double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol 2011; 31: 569-576.
  • Clayton AH, Reddy S, Focht K, Musgnung MS, Fayyad R. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo. J Sex Med. 2013; 10: 768-776.
  • Kornstein SG, Clayton A, Bao W, Guico-Pabia CJ. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. Menopause. 2014; 21(8): 799-806.
  • Coleman KA, Xavier VY, Palmer TL, Meaney JV, Radalj LM, Canny LM. An indirect comparison of the efficacy and safety of desvenlafaxine at the Australian approved doses. CNS Spectr. 2012; 17(3): 131-141.
  • Maity N, Ghosal MK, Gupta A, Sil A, Chakra- borty S, Chatterjee S. Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial. Indian J Pharmacol. 2014; 46(4): 433-437.
  • U.S. Food and Drug Administration. Pristiq: Full prescribing information. [Internet] Revised 2011 Jul [accedido 13 Jul 2014]. Disponible en: http://www.accessdata.fda.gov/drugsat fda_docs/label/2012/021992s030lbl.pdf
  • Anderson HD, Pace WD, Libby AM, West DR, Valuck RJ. Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US Claims Study. Clin Ther. 2012; 34(1): 113-123.
  • Papakostas GI. The efficacy, tolerability and safety of contemporary antidepressants. J Clin Psychiatry. [revista electrónica] 2010; 71 [suppl E1]: e03. [accedido 5 Ago 2014]. Disponible en: http://www.psychiatrist.com/JCP/article/Pa ges/2010/v71e01/v71e0103.aspx
  • Williams VSL, Edim HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010; 24(4): 489-496.
Data source: Dialnet